THE 60-SECOND GUIDE
Tesamorelin
Approved human use · product-specific labels.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
Tesamorelin stimulates the growth-hormone-releasing hormone pathway. Its approved role is to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, a specific indication that does not make it a general weight-loss medicine. [1]
Potential benefits
FDA-approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. Stimulates endogenous growth hormone through the GHRH receptor. The demonstrated benefit is indication-specific—not general weight management. [1]
Evidence & its limits
The label states that long-term cardiovascular safety has not been established and that the medicine is not indicated for weight-loss management. Elevated IGF-1, glucose intolerance or diabetes, fluid retention, and malignancy-related precautions make the narrow indication essential context. [1]
Risks & unknowns
Can cause glucose intolerance, elevated IGF-1, fluid retention, joint or muscle symptoms, and injection-site reactions. Hypersensitivity can occur; the label includes contraindications and pregnancy warnings. Long-term cardiovascular safety has not been established. [1]
Status & scope
Its approved role is to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, a specific indication that does not make it a general weight-loss medicine. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- Current FDA label
- FDA summary review
- Theratechnologies history
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.